SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-18-009021
Filing Date
2018-11-08
Accepted
2018-11-08 16:19:28
Documents
66
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q gemp-20180930x10q.htm 10-Q 1591788
2 EX-10.3 gemp-20180930ex103df9c6f.htm EX-10.3 155993
3 EX-10.4 gemp-20180930ex1043a3b6e.htm EX-10.4 76410
4 EX-31.1 gemp-20180930ex31153d698.htm EX-31.1 17922
5 EX-32.1 gemp-20180930ex321bc9125.htm EX-32.1 12144
  Complete submission text file 0001558370-18-009021.txt   5455730

Data Files

Seq Description Document Type Size
6 EX-101.INS gemp-20180930.xml EX-101.INS 811215
7 EX-101.SCH gemp-20180930.xsd EX-101.SCH 43199
8 EX-101.CAL gemp-20180930_cal.xml EX-101.CAL 34772
9 EX-101.DEF gemp-20180930_def.xml EX-101.DEF 182953
10 EX-101.LAB gemp-20180930_lab.xml EX-101.LAB 387286
11 EX-101.PRE gemp-20180930_pre.xml EX-101.PRE 318148
Mailing Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152
Business Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152 248-980-6538
Gemphire Therapeutics Inc. (Filer) CIK: 0001638287 (see all company filings)

IRS No.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37809 | Film No.: 181169944
SIC: 2834 Pharmaceutical Preparations